← Leaderboards
Aaron Cravens
Revel Pharmaceuticals Inc.
$2,670,620
Attributed
$2,670,620
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,670,620 · 5
By mechanism
R44$1,364,162 · 1
R43$1,306,458 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Tissues”
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Alanna Maguire · Mayo Clinic Rochester$9,942,431
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- Mariet Allen · Mayo Clinic Jacksonville$9,602,417
- Christine W Hockett · Avera Mckennan$8,908,366
Research focus
TissuesInnovationOxidasesAmino AcidsSpecificityEngineeringModificationEnzymesPharmacologic SubstanceDiabetes MellitusHuman TissueExcisionGlycationProteinsReactionFda ApprovedRepairedAdvanced Glycosylation End ProductsBlood GlucoseKineticsComplications Of Diabetes MellitusN(6)-CarboxymethyllysineLysineBlood Vessels
Grant awards (5)
Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts$1,364,162
R44 · FY2025 · AG · contact PI
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy$358,065
R43 · FY2025 · EY · contact PI
An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts$346,755
R43 · FY2024 · GM · contact PI
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease$324,015
R43 · FY2024 · DK · contact PI
Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts$277,623
R43 · FY2023 · AG · contact PI